Trial Profile
A Phase I Trial With Cohort Expansion of BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 08 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 May 2020.
- 20 Jan 2018 Status changed to discontinued.
- 20 Jan 2018 Final results assessing safety and efficacy presented at the 2018 Gastrointestinal Cancers Symposium